-Studies on microRNAs involved in human pathologies for the development of new approaches based on microRNA targeting and replacement; -Biomedical and biotechnological applications of peptide nucleic acids (PNA) and structural analogues directed against mRNA and microRNA; -Development of novel therapeutic strategies using microRNA targeting and combined approaches (miRNA modulation and antitumoral or anti-inflammatory drugs); -Study of natural nutraceutical molecules with anti inflammatory activity for therapeutic applications; -Molecular strategies to modulate gene expression in the treatment of cancer, thalassemia, and cystic fibrosis; -Development of innovative delivery systems for biodrugs; -Molecular strategies to modulate gene expression in the treatment of genetic rare diseases (e.g. beta-thalassemia, cystic fibrosis, Shwachman-Diamond Syndrome); -Gene editing in beta-thalassemia; -Biological evaluation of novel compounds as inducers of erythroid differentiation in the therapy of hematological diseases; -Molecular analysis of circulating microRNAs as peripheral blood biomarkers (liquid biopsy) in cancer patients; -Analysis of transcription factors in gene regulatory networks. -Peptide nucleic acids (PNA) for SPR‑based molecular diagnosis of genetic diseases.